{
  "catalogId": "0ee6973f-1fa5-4ed7-8f09-048be16e1699",
  "name": "BALVERSA 3 MG",
  "status": "draft",
  "category": "prescription",
  "registrationValidity": "valid",
  "registrationNumber": "165 77 36132 00",
  "treatmentDescriptions": "BALVERSA is indicated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma (mUC), that has:- Susceptible FGFR3 or FGFR2 genetiic alterations, and- Progressed during or following at least one line of prior platinum-containing chemotherapy, including within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy.",
  "termsOfIssue": "Prescription required",
  "form": "film coated tablets",
  "route": "per os",
  "site": "",
  "method": "",
  "administrationNotes": "",
  "ingredients": "ERDAFITINIB",
  "codes": {
    "atc5": {
      "system": "WHO ATC Classification",
      "code": "L01EX16",
      "name": "ERDAFITINIB"
    }
  },
  "contraindications": "",
  "sideEffect": "",
  "warnings": "תרופה מוגבלת לרישום ע'י רופא מומחה או הגבלה אחרת",
  "alternativeMedications": [],
  "packaging": [
    {
      "name": "BALVERSA 3 MG 56 TAB",
      "manufacturer": {
        "name": "יאנסן סילג",
        "countryOfOrigin": "IL"
      },
      "strength": {
        "value": 0,
        "unit": ""
      },
      "quantity": {
        "value": 56.0,
        "unit": "units"
      },
      "packagingDescription": "BOTTLE HDPE",
      "shelfLife": "48",
      "storageConditions": "",
      "codes": {
        "moh": "8488",
        "yarpa": "430",
        "pharmasoft": "2746",
        "barcode": "7290014577572"
      },
      "manufacturersAdministrationRecommendation": "",
      "pricing": {
        "currency": "ILS",
        "maxWholesalePrice": "",
        "retailMargin": "",
        "maxRetailPrice": "",
        "maxPriceWithVAT": ""
      }
    }
  ],
  "metadata": {
    "version": "1.4",
    "lastUpdated": "2025-07-31T22:09:11.621393"
  }
}